Scaling a licensed API process from gram to kilo: what to test first
API process scale up checklist for a licensed route: impurity profile, heat and mixing, solvents, crystallisation and the ICH Q3A thresholds to test first.
API process scale up from gram to kilogram should first test impurities, heat release, mixing, solvents and crystallisation. ICH Q3A(R2) sets identification and qualification thresholds for new drug substance impurities at 0.10% and 0.15%, or 1.0 mg a day if lower, for doses up to 2 g a day. Compare kilo-batch impurities with the licensor's gram data.
A route that gives 85% yield and clean material in a 250 ml flask can give 60% yield and a new impurity in a 50 litre reactor. Nothing about the chemistry changed. What changed is how fast heat leaves the vessel, how quickly reagents mix, how long each step takes, and how crystals grow when the solution cools over hours instead of minutes.
A company that licenses an active pharmaceutical ingredient (API) process from an institute or another firm usually receives gram-scale data. Turning that into kilogram batches is the licensee's job. This checklist sets out what to test first, the impurity thresholds that set the targets, and what to ask the licensor for.
Why do processes change on scale-up?
| Factor | Flask (grams) | Reactor (kilograms) | What can go wrong |
|---|---|---|---|
| Heat removal | Fast; large surface area per volume | Slow; small surface area per volume | Temperature spikes, side reactions, runaway risk |
| Mixing | Near instant | Takes time, uneven near the walls | Local excess of reagent, new impurities |
| Addition time | Seconds to minutes | Minutes to hours | Longer exposure of intermediates |
| Work-up | Quick separations | Slow phase separation, emulsions | Product loss, degradation |
| Crystallisation | Fast cooling | Slow cooling, different seeding | Different particle size or form |
| Filtration and drying | Small cakes | Thick cakes, long drying | Retained solvent, degradation |
TRL for chemical processes covers where scale-up sits on the readiness scale. This post focuses on what to test.
What should you test first?
Test in order of risk, with the most expensive surprises first.
| Priority | Test | What you want to know |
|---|---|---|
| 1 | Impurity profile of the licensor's process at small scale | Your baseline: every impurity above the reporting threshold |
| 2 | Heat release of each step | How much heat each reaction gives, and how fast |
| 3 | Addition rate and mixing sensitivity | Whether slower addition changes yield or impurities |
| 4 | Hold times | Whether intermediates degrade if a step waits hours |
| 5 | Solvent and work-up | Whether solvents, extractions and washes work at volume |
| 6 | Crystallisation | Particle size, form and purity under slow cooling |
| 7 | Filtration and drying | Cake behaviour, residual solvents, stability on drying |
Start by repeating the licensor's process at gram scale in your own lab, with your own raw materials, before any scale-up. If you cannot reproduce their impurity profile and yield there, scale will only make the gap worse.
Gram to kilo in order of risk
Which impurity thresholds set the targets?
For a new drug substance, ICH Q3A(R2) sets three thresholds, based on maximum daily dose.
| Maximum daily dose | Reporting threshold | Identification threshold | Qualification threshold |
|---|---|---|---|
| Up to 2 g a day | 0.05% | 0.10% or 1.0 mg a day intake, whichever is lower | 0.15% or 1.0 mg a day intake, whichever is lower |
| More than 2 g a day | 0.03% | 0.05% | 0.05% |
Source: ICH Q3A(R2), Impurities in New Drug Substances, Attachment 1. Lower thresholds can apply if an impurity is unusually toxic.
Section 3.1 of the guideline says the impurity profile of batches made by the proposed commercial process should be compared with batches used in development, and any differences discussed. In practice, that comparison starts at your first kilo batch. At a dose under 2 g a day, a new impurity above 0.10% (or 1.0 mg a day intake, if lower) needs identifying; above 0.15% (or 1.0 mg a day, if lower) it needs qualifying, which can mean safety studies. Finding one early, while you can still change the process, is far cheaper than finding it in validation batches.
Gram batch or kilo batch
Compare impurity profiles batch by batch, starting at the first kilo run.
What should you ask the licensor for?
A licence for an API process is mostly a know-how licence. The quality of the hand-over decides how much you repeat. Know-how licences covers the contract; for scale-up, list these as deliverables.
| Deliverable | Why you need it |
|---|---|
| Full process description | Every quantity, temperature, time and order of addition |
| Batch records from gram runs | What actually happened, including failed batches |
| Analytical methods and data | To compare your impurity profile with theirs |
| Impurity reference standards, if available | To identify peaks quickly |
| Known failure modes | Steps that are sensitive to moisture, air or temperature |
| Technical support days | Help when your first batches differ |
Ask especially for failed batch records. They show where the process is fragile, which a set of clean results never does.
What about manufacturing rules?
Kilo batches made for development differ from commercial production. Even so, plan now for the rules that will apply. Revised Schedule M, notified on 28 December 2023, sets good manufacturing practice requirements for drug manufacturers. According to the Health Ministry's February 2025 release, firms with turnover above ₹250 crore had to comply from 28 June 2024, and firms with turnover of ₹250 crore or less that submitted an upgrade plan in Form A within three months of 11 February 2025 received an extension to 31 December 2025.
Source: copy of the PIB release on the revised Schedule M extension, 12 February 2025. Check with the licensing authority what applies to your plant and product before commercial batches.
A worked example
Illustration with invented figures. A Hyderabad MSME licenses a five-step route to an API from an institute and plans to reach a 5 kg batch.
| Stage | Work | Cost (₹) |
|---|---|---|
| Reproduce at 10 g | Three runs with the firm's raw materials | 2,50,000 |
| Impurity mapping | Method transfer, identification of three impurities above 0.05% | 4,00,000 |
| Heat release studies | Calorimetry on steps 2 and 4 | 3,00,000 |
| Stress studies | Slow addition and hold-time runs | 2,00,000 |
| 500 g and 5 kg batches | Pilot reactor time, materials, analysis | 9,00,000 |
| Total | 20,50,000 |
At the 500 g stage, a new impurity appeared at 0.12% after a longer hold in step 3. The team cut the hold time and changed the work-up, bringing it below 0.05% before the 5 kg batch. Found at 50 kg, the same problem would have cost a batch worth more than the whole study.
Common mistakes
- Scaling up before reproducing the licensor's results in your own lab.
- Ignoring heat release until a temperature spike.
- Testing only the main product and not the impurity profile.
- Not asking for failed batch records.
- Assuming crystals formed in a flask will match those from a reactor.
My view: impurity mapping at gram scale is easy to rush, and it is the step that saves the most money, because every later batch is judged against it. I am less certain how much support a given licensor can give, since many institute labs move on to new work once a licence is signed; write the support days into the agreement.
If your team needs lab R&D support for this kind of work, Zernyx Labs does prototyping and lab R&D for biotech, pharma and cosmetics.
Common questions
What should be tested first when scaling up a licensed API process?
The impurity profile, the heat released by each step, mixing and addition rates, solvent and work-up choices, and the crystallisation that sets particle form and size. These change most between a flask and a reactor, and problems with them are costly to find late.
What impurity levels does ICH Q3A allow?
ICH Q3A(R2) sets thresholds by maximum daily dose. For up to 2 g a day, impurities above 0.05% are reported, above 0.10% or 1.0 mg a day (whichever is lower) identified, and above 0.15% or 1.0 mg a day qualified. For more than 2 g a day the thresholds are 0.03%, 0.05% and 0.05%.
What should a licensee get from the licensor for scale-up?
The full process description, the gram-scale batch records and analytical data, impurity reference standards where available, known failure modes, and some days of technical support. A know-how licence should list these as deliverables.
What are the revised Schedule M deadlines?
Revised Schedule M, notified on 28 December 2023, sets good manufacturing practice requirements for drug manufacturers. Firms with turnover above ₹250 crore had to comply from 28 June 2024; smaller firms that filed an upgrade plan in Form A received an extension to 31 December 2025.